Jim Ziegler
Equibles does not estimate personal net worth.
Get an email with a short summary when Iovance Biotherapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get IOVA alertsAbout Jim Ziegler
Geron Corp reported in an 8-K filed October 14, 2025 that Jim Ziegler resigned as Executive Vice President, Chief Commercial Officer, effective October 15, 2025. Iovance Biotherapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Iovance Biotherapeutics, Inc. includes Frederick G. Vogt, Ph.D. (CEO), Frederick Vogt (CEO and General Counsel), Corleen Roche (CFO) and 7 others.
“Effective October 15, 2025, Andrew J. Grethlein, Ph.D., Executive Vice President, Chief Operating Officer and Jim Ziegler, Executive Vice President, Chief Commercial Officer will depart from the Company.”
Affiliation history
-
Iovance Biotherapeutics, Inc. (IOVA)
Source not stated
Current -
Geron Corp (GERN)
Source not stated
Start not stated–2025-10-15
Company network
Leadership on record at Iovance Biotherapeutics, Inc.
- Frederick G. Vogt, Ph.D. CEO
- Frederick Vogt CEO, General Counsel
- Corleen Roche CFO
- Jean-Marc Bellemin CFO
- Igor Bilinsky COO
- Igor Bilinsky, Ph.D. COO
- Matthew W. Rosinack Chief Accounting Officer
- Michael C. Swartzburg Chief Accounting Officer
- Athena Countouriotis Board Member
- Iain Dukes Board Member